Summary
PREDICT1 is an observational study that developed and validated a blood proteomic classifier to predict clinical benefit from carboplatin–pemetrexed chemotherapy in advanced or recurrent non-squamous non-small cell lung cancer. Using mass spectrometry proteomic analysis of pre-treatment blood samples from 96 patients in a training cohort, the researchers constructed a weighted-voting classifier that successfully stratified an independent validation cohort (n=94) into good and poor responder groups. The good responder group demonstrated significantly higher objective response rates (30.9% vs 5.1%), longer progression-free survival (6.0 vs 2.3 months), and substantially improved overall survival (25.7 vs 5.1 months) compared to the poor responder group.
UK applicability
This study's findings on proteomic biomarkers are relevant to UK oncology practice insofar as carboplatin–pemetrexed remains a treatment option for NSCLC patients; however, the classifier's clinical utility in UK populations would require validation in UK cohorts and integration into NHS diagnostic pathways.
Key measures
Objective response rate (RECIST v1.1), progression-free survival (PFS), overall survival (OS), proteomic profiles by mass spectrometry, weighted voting classifier accuracy
Outcomes reported
The study identified a proteomic classifier based on blood biomarkers that predicts clinical benefit from carboplatin and pemetrexed chemotherapy in patients with non-squamous non-small cell lung cancer. The classifier distinguished good responders from poor responders based on objective response rates, progression-free survival, and overall survival.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.